|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
3
|
Resverlogix Corp.
|
May 11, 2019 11:07PM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
6
|
Resverlogix Corp.
|
May 15, 2019 07:54PM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
7
|
Resverlogix Corp.
|
May 11, 2019 08:11AM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
3
|
Resverlogix Corp.
|
May 16, 2019 10:57AM
|
|
Re: Resverlogix presenting at Vascular Discovery 2019 next week
|
4
|
Resverlogix Corp.
|
May 14, 2019 04:16PM
|
|
Re: Resverlogix presented at Vascular Discovery 2018
|
4
|
Resverlogix Corp.
|
May 17, 2018 04:29PM
|
|
Re: Resverlogix presentation at European Meeting on Complement in Human Disease meeting
|
3
|
Resverlogix Corp.
|
Sep 08, 2017 05:10PM
|
|
Re: Resverlogix presentation at European Meeting on Complement in Human Disease meeting
|
3
|
Resverlogix Corp.
|
Sep 08, 2017 06:43PM
|
|
Re: Resverlogix poster at American Diabetes Association meeting on Sunday June 7
|
3
|
Resverlogix Corp.
|
Jun 06, 2015 12:58PM
|
|
Re: Resverlogix October 2018 events
|
3
|
Resverlogix Corp.
|
Oct 17, 2018 10:18PM
|
|
Re: Resverlogix October 2018 events
|
6
|
Resverlogix Corp.
|
Oct 18, 2018 08:46AM
|
|
Re: Resverlogix October 2018 events
|
4
|
Resverlogix Corp.
|
Oct 18, 2018 09:50AM
|
|
Re: Resverlogix NYAS Symposium notes
|
|
Resverlogix Corp.
|
Apr 29, 2016 03:37PM
|
|
Re: Resverlogix now listed as a Presenting Company at Biopharm America
|
2
|
Resverlogix Corp.
|
Sep 22, 2017 10:26AM
|
|
Re: Resverlogix now listed as a Presenting Company at Biopharm America
|
1
|
Resverlogix Corp.
|
Sep 22, 2017 12:02PM
|
|
Re: Resverlogix needs to host another R&D Day for Investors and Analysts
|
|
Resverlogix Corp.
|
Jul 03, 2018 04:52PM
|
|
Re: Resverlogix just tweeted this video...
|
1
|
Resverlogix Corp.
|
Jan 27, 2017 08:40AM
|
|
Re: Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
|
5
|
Resverlogix Corp.
|
Feb 13, 2017 10:41AM
|
|
Re: Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the “Shock and Kill” Approach
|
3
|
Resverlogix Corp.
|
Jun 07, 2018 09:55AM
|
|
Re: Resverlogix has been shortlisted for the Buzz of Bio award "Pipelines of Promise...
|
2
|
Resverlogix Corp.
|
Apr 04, 2017 09:37AM
|
